Many Beclin-1 monoallelic deletions have been observed in breast, ovarian, and prostate cancers; the disruption of both Beclin-1 alleles results in the suppression of cell proliferation and autophagy in vivo [64]. This evidence concerns the gene BECN1 and prostate cancer.